Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Isabelle Rooney et al.|The Lancet Oncology|2016Cited by 1k
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Isabelle Rooney et al.|The Lancet Oncology|2018Cited by 658
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced <i>BRAF</i>-mutated melanoma.James Larkin, Antoni Ribas, Stephen P. Hack et al.|Journal of Clinical Oncology|2015Cited by 48
Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with <i>BRAF</i><sup>V600</sup> mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.Brigitte Dréno, James Larkin, Isabelle Rooney et al.|Journal of Clinical Oncology|2018Cited by 27
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanomaBrigitte Dréno, Antoni Ribas, Isabelle Rooney et al.|British Journal of Cancer|2018Cited by 24